Celerion, a specialist in early clinical research, has appointed John Horkulak as Executive Director, Eurasian Site Operations to help expand the company’s early phase patient capabilities in Europe and Asia.
Horkulak will focus on identifying and building partnerships with specialist early phase organisations with access to target patient populations in Europe and Asia. By leveraging his knowledge of sites in Central and Eastern Europe that perform pharmacokinetic and pharmacodynamic studies in patients with hepatic and renal insufficiency, diabetes, rheumatoid arthritis, as well as asthma and COPD, he will complement services offered at Celerion’s clinic in Belfast, Northern Ireland, UK.
In addition, he will explore new relationships to build patient access in Europe and Asia for supporting early clinical studies in neurodegenerative diseases, cardiovascular disease and oncology.
Horkulak comes to Celerion with more than 30 years of experience in drug development at both pharmaceutical companies and contract research organisations (CROs). His expertise encompasses Phase I and II clinical study operations, primarily in Central and Eastern Europe, as well as general management.
Horkulak was the founder and CEO of a niche CRO called Pharmacon Research, and after its successful acquisition, he became Vice President of Patient Pharmacology at a leading CRO.
